Collplant biotechnologies announces first quarter financial results for 2024 and provides corporate update

Additional large-animal study with commercial-size breast implants commenced in december 2023 expected to conclude in june 2024 cash and cash equivalents balance as of march 31, 2024, was $23.2 million conference call and webcast to discuss its financial results and corporate updates on may 29 at 10:00 a.m. eastern daylight time (details herein) rehovot, israel , may 29, 2024 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced results for the first quarter ended 2024 and provided a corporate update.
CLGN Ratings Summary
CLGN Quant Ranking